T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients

Primary or reactivation of latent human cytomegalovirus (CMV) infection is a common complication within the first six months after solid-organ transplantation (SOT). SOT patients with a serological mismatch between the donor and the recipient (CMV donor (D) IgG +/recipient (R) -) are at high-risk for the development of CMV infection. In addition, CMV seropositive patients (D+/R  + and D-/R+) are considered intermediate risk, whilst the CMV D-/R- constellation is considered low risk. [1,2]

Source: Journal of Clinical Virology - June 11, 2018 Category: Virology Authors: Smaranda Gliga, Johannes Korth, Adalbert Krawczyk, Benjamin Wilde, Peter A. Horn, Oliver Witzke, Monika Lindemann, Melanie Fiedler Source Type: research